We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+10.35%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$113M
AUM Growth
-$2.14M
(-1.9%)
Cap. Flow
-$5.51M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
14.17%
Holding
280
New
34
Increased
61
Reduced
100
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Financials Index ETF
FNCL
|
+$1.46M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.13M |
| 3 |
MediciNova
MNOV
|
+$969K |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$866K |
| 5 |
CLSD
Clearside Biomedical
CLSD
|
+$856K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Information Technology Index ETF
FTEC
|
+$2.78M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$1.32M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
+$1.22M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$1.01M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$938K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.9% |
| 2 | Financials | 0.8% |
| 3 | Technology | 0.58% |
| 4 | Consumer Discretionary | 0.4% |
| 5 | Energy | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDUS
101
DELISTED
Radius Health, Inc.
RDUS
| $700K | 0.62% |
23,749
-7,264
| -23% | -$230K |
|
102
Inovio Pharmaceuticals
INO
$79.8M
| $699K | 0.62% |
14,864
+299
| +2% | +$16.5K |
|
|
EPZM
103
DELISTED
Epizyme, Inc
EPZM
| $694K | 0.61% |
51,203
-8,127
| -14% | -$126K |
|
104
Biogen
BIIB
$29.9B
| $693K | 0.61% |
2,388
-438
| -15% | -$123K |
|
|
BPMC
105
DELISTED
Blueprint Medicines
BPMC
| $688K | 0.61% |
10,840
+811
| +8% | +$64.5K |
|
106
Theravance Biopharma
TBPH
$874M
| $682K | 0.6% |
30,055
-2,934
| -9% | -$69.7K |
|
107
Denali Therapeutics
DNLI
$3.67B
| $680K | 0.6% |
+44,617
| New | +$841K |
|
108
Lexicon Pharmaceuticals
LXRX
$1.02B
| $680K | 0.6% |
56,636
-33,209
| -37% | -$340K |
|
109
Insmed
INSM
$23.2B
| $679K | 0.6% |
28,718
+4,309
| +18% | +$111K |
|
110
Ultragenyx Pharmaceutical
RARE
$2.65B
| $676K | 0.6% |
8,794
-8,189
| -48% | -$529K |
|
|
ITCI
111
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $675K | 0.6% |
38,174
-11,914
| -24% | -$242K |
|
112
Adicet Bio
ACET
$72.8M
| $673K | 0.6% |
+657
| New | +$707K |
|
113
Omeros
OMER
$709M
| $673K | 0.6% |
37,076
-10,200
| -22% | -$177K |
|
114
Corbus Pharmaceuticals
CRBP
$170M
| $671K | 0.59% |
4,430
+1,014
| +30% | +$184K |
|
115
Incyte
INCY
$23.5B
| $671K | 0.59% |
10,024
+487
| +5% | +$33.3K |
|
116
Novavax
NVAX
$1.23B
| $671K | 0.59% |
25,048
-3,179
| -11% | -$107K |
|
|
ACOR
117
DELISTED
Acorda Therapeutics
ACOR
| $665K | 0.59% |
193
-171
| -47% | -$524K |
|
|
PTLA
118
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $664K | 0.59% |
17,590
-1,613
| -8% | -$61.7K |
|
119
Viking Therapeutics
VKTX
$4.04B
| $658K | 0.58% |
+69,305
| New | +$461K |
|
|
AGEN
120
Agenus
AGEN
$249M
| $656K | 0.58% |
14,716
+3,887
| +36% | +$262K |
|
|
MNTA
121
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $649K | 0.57% |
31,740
-36,744
| -54% | -$788K |
|
122
Halozyme
HALO
$9.72B
| $648K | 0.57% |
38,423
-7,397
| -16% | -$140K |
|
|
BLUE
123
DELISTED
bluebird bio
BLUE
| $647K | 0.57% |
318
-3
| -0.9% | -$6.84K |
|
124
Agios Pharmaceuticals
AGIO
$2.16B
| $645K | 0.57% |
7,652
-6,753
| -47% | -$589K |
|
125
Ionis Pharmaceuticals
IONS
$9.35B
| $642K | 0.57% |
15,418
-2,164
| -12% | -$95.9K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2018 Portfolio in Review
As of Q2 2018, Virtus ETF Advisers held 280 positions worth $113M, down 1.9% from $115M the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Virtus ETF Advisers withdrew a net $5.51M in Q2 2018, closing 19 positions and reducing 100 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $1.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Fidelity MSCI Financials Index ETF worth $1.41M.
- Virtus ETF Advisers's largest Q2 2018 buy was Fidelity MSCI Financials Index ETF: 35,927 shares worth $1.41M.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q2 2018, an estimated $1.13M increase.
- Virtus ETF Advisers's biggest Q2 2018 reduction was Fidelity MSCI Information Technology Index ETF, cutting an estimated $2.78M.
- Virtus ETF Advisers fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2018, selling an estimated $1.32M.
- Virtus ETF Advisers's ten largest holdings make up 14% of its $113M portfolio in Q2 2018.
- Virtus ETF Advisers opened 34 new positions and closed 19 in Q2 2018.
- Virtus ETF Advisers's portfolio value fell 1.9% quarter-over-quarter to $113M.
Based on Virtus ETF Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.